Abbott Laboratories Corporation

Abbvie Inc.

Abbvie Bahamas Limited

Abbvie Ireland Unlimited Company

John E Hengeveld

John K Pratt

Rolf Wagner

Todd Warren Rockway

John T Randolph

Dachun Liu

Geoff G Z Zhang

David A Betebenner

Douglas K Hutchinson

Rodger F Henry

Clarence J Maring

Kent D Stewart

Yi Gao

Anthony Ralph Haight

David A DeGoey

Allan C Krueger

Pamela L Donner

David M Barnes

Zhonghua Pei

Warren M Kati

Charles A Flentge

Kenton L Longenecker

Michael D Tufano

Thomas W Von Geldern

Geoff G Zhang

Shuang Chen

Christopher E Motter

Xiaochun Lou

Yaya Liu

Richard R Copp, Jr

Xiaofeng Li

Ramiya H Premchandran

Brian J Kotecki

Maureen Ann McLaughlin

David A Degoey

Philip E Bauer

Ashok K Gupta

Jufang Barkalow

Jinshyun Ruth Wu-Wong

David B Murphey

Kimberly Ann Allen

Rodney M Mittag

Brian S Moon

Xiaoxing Dong

Greg S Lannoye

Brian T Fohey

Elise H Leese

Dennis M Abad

William T Noonan

Peggy P Huang

Thaddeus S Franczyk

Kathy Sarris

Thaddeus S Franczyk Ii

Thaddeus S Ii Franczyk

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Anti-infective agents and uses thereof

The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Vitamin D receptor activators and methods of making

The present invention provides a simple, 1-step process for preparing a N-(aryl or heteroaryl)-hydroxyurea comprising reacting the corresponding alcohol, ester or ether with hydroxyurea and acid. This reaction is particularly useful for preparing a benzo[b]thienyl substituted N-hydroxyurea of formula: ##STR1## from compound 1: ##STR2## by reacting compound 1 with hydroxyurea and acid. R.sup.1 is selected from the group consisting of hydrogen, 1-6 carbon alkyl, 1-6 carbon alkoxy, and halogen; R.sup.2 is an 1-4 carbon alkyl; and R.sup.3 is selected from the group consisting of hydrogen, acyl, methyl, ethyl and mixtures thereof. Additional steps to isolate the pure bulk product follow.

Synthesis and isolation of N-(aryl or heteroaryl)-alkyl-N-hydroxyurea

Disclosed is an improved and efficient process for N-desmethylating the 3'-amino nitrogen of erythromycins and for converting the 3'-N-desmethylated erythromycins into 3'-N-substituted derivatives of 8,9-anhydro-erythromycin 6,9-hemiketals.

Process for N-desmethylating erythromycins and derivatives thereof

Growing community of inventors

Kenosha, WI, United States of America

John E Hengeveld